어린이 유치 어금니에 지르코니아 크라운을 씌운 후 교합 적응과 씹는 힘 변화를 관찰하는 연구입니다.

All participants will receive pulp therapy and restoration of primary molars with prefabricated zirconia crowns. Bite force and occlusal contacts will be measured using the T-Scan digital occlusal analysis system at baseline, 2 weeks, and 4 weeks post-restoration. Participants act as their own control, with pre-restoration measurements compared to post-restoration outcomes. No comparison or additional study arms are included.

Participants will receive pulp therapy followed by restoration of primary molars with prefabricated zirconia crowns according to standard pediatric dental protocols. Occlusal function and bite force will be assessed using the T-Scan digital occlusal analysis system at baseline, and at 2 and 4 weeks post-restoration. This intervention combines a therapeutic dental procedure with objective, instrumented measurement of occlusal adaptation, allowing participants to act as their own controls. Follow-up visits will monitor crown fit, occlusal contacts, and bite force changes over time.

Pulp Therapy and Zirconia Crown Restoration of Primary Molars with T-Scan Occlusal Analysis

Lama Hatem Mohamed Kamal Belal, BDS

In patients with NCCN high or unfavorable intermediate risk prostate cancer - radical prostatectomy with limited lymph node dissection (incl. obturator + / - external iliac lymph nodes bilaterally). In patients with NCCN low or favorable intermediate risk prostate cancer - radical prostatectomy with no lymph nodes dissection bilaterally.

Radical prostatectomy with limited / no lymph node dissection

In patients with NCCN high or unfavorable intermediate risk prostate cancer - radical prostatectomy with extended lymph node dissection (incl. external iliac, obturator, internal iliac and common iliac nodes up to ureter bilaterally).

In patients with NCCN low or favorable intermediate risk prostate cancer - radical prostatectomy with limited lymph node dissection (incl. obturator + / - external iliac lymph nodes bilaterally).

Radical prostatectomy with extended / limited lymph node dissection

Alexander I Rolevich, Dr.

Maxim V Trunin

Patients receive selumetinib PO BID and olaparib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

Biopsy Procedure

Biospecimen Collection

Bone Marrow Aspiration and Biopsy

Computed Tomography

Echocardiography Test

Multigated Acquisition Scan

Olaparib

Selumetinib Sulfate

Patients receive selumetinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who experience progression may elect to cross over to Arm I provided they have not had dose limiting toxicities to monotherapy selumetinib. Patients also undergo a tumor biopsy and blood collection during screening and on study, as well as ECHO or MUGA, and CT scans throughout the trial. Patients may undergo bone marrow aspiration or biopsy as clinically indicated.

Site Public Contact

Luis J. Santos Reyes

Rebecca C. Arend

Nathaniel L. Jones

Dan S. Zuckerman

Sagun Shrestha

John A. Ellerton

Omid Hamid

Timothy E. Byun

Babak Litkouhi

Chukwuemeka (Emeka) V. Ikpeazu

Grace M. Choong

Michael E. Carney

Tareq Al baghdadi

John M. Schallenkamp

Antony Ruggeri

Bryan A. Faller

Deimante M. Tamkus

Rajul Kothari

Katherine C. Kurnit

Georgina Cheng

Mary T. Jenkins Vogel

Seema Harichand-Herdt

Richard L. Deming

Susanne M. Arnold

Katrina S. Wade

Leslie S. Bradford

Sarah J. Sinclair

Ranee Mehra

Christopher Tarney

A P. Chen

Alexander B. Olawaiye

Sarah E. Paraghamian

Tashanna K. Myers

Patients receive filgrastim SC or IV QD on days 1-6 and ASTX727 PO QD on days 2-6. Patients may receive decitabine PO QD on days 2-6 to achieve the appropriate dose. Cycles repeat every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo bone marrow aspiration and biopsy and blood sample collection throughout the study and may undergo lumbar puncture and diagnostic imaging throughout the study.

Bone Marrow Aspiration

Bone Marrow Biopsy

Decitabine

Decitabine and Cedazuridine

Filgrastim

Imaging Procedure

Lumbar Puncture

레어노트에 환자 모임 등록

회원 모집 중

비정형 용혈요독증후군 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

비정형 용혈요독증후군(aHUS) 카카오톡 오픈채팅방

오픈 채팅방

저인산효소증 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

저인산효소증(HPP) 카카오톡 오픈채팅방

진행성 가족성 간내 담즙정체증 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

진행성 가족성 간내 담즙정체증(PFIC) 카카오톡 오픈채팅방

발작성 야간혈색소뇨증 환우·보호자들이 모여있는 오픈 채팅방으로 질환 및 치료에 대한 정보를 공유하고, 일상을 공감합니다.

발작성 야간혈색소뇨증(PNH) 카카오톡 오픈채팅방

임상시험 현황

T-스캔 교합 분석을 이용한 유치 어금니의 치수 치료 및 지르코니아 크라운 수복

광범위/제한적 림프절 절제를 동반한 근치적 전립선 절제술, 제한적/림프절 절제 없음

생검 절차, 생체 시료 채취, 골수 흡인 및 생검, 컴퓨터 단층 촬영, 심초음파 검사, 다중 게이트 획득 스캔, 올라파립, 셀루메티닙 황산염

생체 시료 채취, 골수 흡인, 골수 생검, 데시타빈, 데시타빈 및 세다주리딘, 필그라스팀, 영상 촬영 절차, 요추 천자

환자 모임 정보